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AIMS
Inﬂammation and organ failure have been reported to have an impact on cytochrome P450 (CYP) 3A-mediated clearance of
midazolam in critically ill children. Our aim was to evaluate a previously developed population pharmacokinetic model both in
critically ill children and other populations, in order to allow the model to be used to guide dosing in clinical practice.
METHODS
The model was evaluated externally in 136 individuals, including (pre)term neonates, infants, children and adults (body weight
0.77–90 kg, C-reactive protein level 0.1–341 mg l–1 and 0–4 failing organs) using graphical and numerical diagnostics.
RESULTS
The pharmacokinetic model predicted midazolam clearance and plasma concentrations without bias in postoperative or critically
ill paediatric patients and term neonates [median prediction error (MPE) <30%]. Using the model for extrapolation resulted in
well-predicted clearance values in critically ill and healthy adults (MPE <30%), while clearance in preterm neonates was over
predicted (MPE >180%).
CONCLUSION
The recently published pharmacokinetic model for midazolam, quantifying the inﬂuence of maturation, inﬂammation and organ
failure in children, yields unbiased clearance predictions and can therefore be used for dosing instructions in term neonates,
children and adults with varying levels of critical illness, including healthy adults, but not for extrapolation to preterm neonates.
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WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT
• Recently, the impact of inﬂammation and organ failure on cytochrome P450 (CYP) 3A-mediated midazolam metabolism
has been quantiﬁed in critically ill children.
• Before population pharmacokinetic models can be used for clinical decision making and deriving dosing recommenda-
tions, they should be thoroughly evaluated in external datasets.
WHAT THIS STUDY ADDS
• Metabolic midazolam clearance can be accurately predicted in critically ill term neonates, infants and children using C-
reactive protein level and the number of failing organs.
• While extrapolation to preterm neonates on the basis of this model leads to considerable overprediction of metabolic
midazolam clearance, extrapolation to adults and patients beyond the studied disease severity levels yielded unbiased
midazolam clearance predictions.
Introduction
Various studies suggest that cytochrome P450 3A (CYP3A)-
mediated drug metabolism may be reduced by inﬂammation
and disease [1–5]. Decreases in CYP3A-mediated clearance
may result in overdosing and side effects in certain patient
populations. A previous study in critically ill children showed
substantially reduced CYP3A-mediated clearance of midazo-
lam in patients with inﬂammation and organ failure [6]. A
population pharmacokinetic (PK) model for midazolam was
developed, based on data both from critically ill term neo-
nates and children between 0 and 17 years of age who were
on mechanical ventilator support [6]. Increased inﬂamma-
tion, reﬂected by a 10-fold increase in the inﬂammatory
marker C-reactive protein (CRP) concentrations from 32 mg
l–1 to 300 mg l–1, was found to correlate with a 50% reduction
in midazolam clearance in this population. Furthermore, an
increase in disease severity, reﬂected by the number of failing
organs (cardiovascular, renal, respiratory, haematological
and/or hepatic failure), e.g. increasing from one to three or
>3, correlates with 35% or 47% reduced midazolam clear-
ance, respectively (Figure 1).
To allow population models to be used for clinical deci-
sion making (e.g. for deriving dosing recommendations),
they should be evaluated thoroughly [7–9]. Without proper
validation and evaluation, models can only be regarded as de-
scriptive rather than predictive, thereby limiting their safe
use for clinical and research applications [8]. Three categories
in model evaluation with increasing order of quality have
been described [9–11]: basic internal methods, advanced in-
ternal methods and external model evaluation. Marsot et al.
[10] found that only 10% of the population models in paedi-
atric subjects from neonates to 2 years of age developed up to
2010 were evaluated externally, even though this step is es-
sential if the model is to be used to predict adequate dosing
regimens in routine clinical practice. An external validation
is based on new data that were not used for model
development. A valid population model should at least be
able to predict accurately data from patients with a distribu-
tion of characteristics (e.g. weight/age range or disease
severity) comparable with those of the patient population in-
cluded inmodel development [8].When amodel is applied to
predict pharmacokinetics in individuals with characteristics
outside the range of the population used in model develop-
ment, this not an external validation, but a form of extrapola-
tion and this may affect the model’s predictions in the new
population [12].
The previously developed PK model for quantifying
CYP3A-mediated midazolam clearance in critically ill children
[6] has the potential to deﬁnemidazolam dosing regimens that
reliably achieve target plasma concentrations. The aim of the
present study was to evaluate the predictive performance of
the population PK model in external data from patients with
the same patient characteristics as in the original model (i.e.
critically ill children, infants and term neonates). Moreover,
the extrapolation potential of the model was investigated by
evaluating its predictive performance in populations beyond
the studied age range (i.e. preterm neonates or adults) and
disease severity (healthy state).
Methods
Patients and data
From the literature, data from six studies were available that
could be used for this external validation and extrapolation
study [13–18]. These studies covered different patient
Figure 1
Model-predicted paediatric midazolam clearance for different levels
of inﬂammation, as reﬂected by C-reactive protein (CRP) concentra-
tions of 10mg l–1, 32mg l–1 and 300mg l–1 (top to bottom), and dis-
ease severity scenarios, reﬂected by number of organ failures
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populations, ranging largely in age from preterm neonates to
adults with different disease severity levels. All studies had
been approved by ethics committees, and informed (paren-
tal) consent had been obtained. Table 1 gives an overview of
the patient and study characteristics of the available data for
external validation [13, 14] and extrapolation [15–18] as well
as of the internal data from the original model development
[6] as a comparison. The new data included 136 preterm neo-
nates, infants, children and adults, all of whom received in-
travenous midazolam. Organ failure, scored from 0–5, was
deﬁned based on a maximum sub-score for cardiovascular, re-
nal, respiratory, haematological and hepatic failure on the
paediatric logistic organ dysfunction (PELOD) score [19] for
the paediatric subjects or on the Sequential Organ Failure As-
sessment (SOFA) score [20] for the adult subjects. For all study
participants, information on respiratory function was
known, while information on the function of other organs
or on CRP levels was not always reported. For missing CRP
data in preterm neonates and healthy adult volunteers,
values for a healthy individual were assumed (i.e. a CRP con-
centration of 10 mg l–1). In the case of missing sub-scores on
organ dysfunction, it was assumed that there was no organ
failure. For missing CRP values in critically ill adults [18], a
CRP concentration of 32 mg l–1 was assumed, which was the
median CRP value in the previously reported model [6]
(Table 1; see section on original model, below). In total, 10
observations from two individuals were discarded because of
a substantial increase in the plasma midazolam concentra-
tion without a recorded prior dosing event; for at least one
individual, this was known to be due to ﬂushing of the
intravenous line in the contralateral arm before sampling.
Original model
The original population PK model consisted of a two-
compartment model in which the effect of body weight, in-
ﬂammation, and organ failure on midazolam clearance in
critically ill term neonates and children up to the age of
17 years was quantiﬁed [6]. For a median patient of 5 kg body
weight, with a CRP concentration of 32mg l–1 and one failing
organ, clearance was 1.29 l h–1 [6]. Individual clearance (CL)
was quantiﬁed as follows:
CLi ¼ CL5 kg  WTi=5ð Þ1:02 CRPi=32ð Þ–0:312 (1)
in which CL5 kg varies for different numbers of failing organs,
with a value of 1.29 l h–1, 0.96 l h–1, 0.83 l h–1 or 0.67 l h–1 for
one, two, three or >3 failing organs, respectively, WTi is the
body weight (in kg) of individual i, and CRPi is the CRP con-
centration (in mg l–1) of this individual. This corresponds to
a clearance of 19.0 l h–1 for an individual with a body weight
of 70 kg, a CRP concentration of 32 mg l–1 and one failing or-
gan. The volume of distribution in the central compartment
for individual i was:
V1i lð Þ ¼ 3:28· WTi=5ð Þ1:34 (2)
corresponding to 113 l for a 70 kg individual, and the periph-
eral distribution volume and intercompartmental clearance
were 5.44 l and 1.52 l h–1, respectively.
Model evaluation
The predictive performance of the PK model was evaluated
using several tools. First, we obtained population and indi-
vidual concentration predictions using the model and its
published model parameters in NONMEM (version 7.3,
ICON, Ellicott City, MD, USA). Using R (version 3.2.2) and
R-studio (version 0.98.1078), goodness-of-ﬁt plots were con-
structed. Concentration predictions were compared visually
with the observed concentrations, and the distribution of
conditionally weighted residuals (CWRES) vs. the population
prediction of the plasma concentrations and vs. time were
assessed visually. When model predictions are unbiased,
CWRES are randomly distributed around zero. Additionally,
we plotted individual and population clearance predictions
vs. the most dominant covariate (i.e. body weight), to assess
the accuracy of the covariate model. Furthermore, bias was
calculated per dataset by taking the median of the prediction
error (PE):
PE ¼ pred  obsð Þ100
obs
(3)
in which pred is the predicted concentration or the individu-
ally predicted clearance, and obs the observed concentration
or the population-predicted clearance to evaluate the PE in
concentration and clearance, respectively. An MPE of <30%
was considered to be an accurate prediction. Moreover, a
normalized prediction distribution error (NPDE) analysis
was performed using the NPDE package in R [21]. For each ob-
served concentration in the external datasets, 1000 midazo-
lam concentrations were simulated. The simulations were
based on the dosing regimen, body weight, CRP concentra-
tions and level of organ failure of the patients, and on the pa-
rameter values, including interindividual and residual
variability, that were obtained for the original model
(Table 2). These 1000 predicted concentrations were com-
pared with the observed concentrations in the external
datasets. For accurate concentration predictions, the mean
of the NPDE is expected to be 0 and an adequate description
of the variability in the model is expected to yield a variance
in the NPDE distribution of 1.
Results
Overall, 1045 plasma concentrations from 136 subjects, aged
between 1 day and 84 years, with a body weight ranging from
0.77 kg to 90 kg, were available for the external validation
and extrapolation (Table 1) [13–18]. To compare, Table 1 also
shows the data used for development of the original model,
which were collected in 83 critically ill term neonates and
children, ranging in age from 1 day to 17 years [6]. The sub-
jects for the external validation included 18 critically ill chil-
dren [13] and 26 children following cardiac bypass surgery
[14], who were within the age and body weight range of the
model building dataset and had comparable CRP concentra-
tions and levels of organ failure. Furthermore, 55 preterm ne-
onates ranging in age between 1 day and 44 days [15, 16], 17
critically ill adults without alcohol abuse [18] and 20 healthy
adults [17] were included to evaluate the extrapolation po-
tential of the model predictions to patients outside the
J. M. Brussee et al.
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studied age and weight range and with different levels of dis-
ease severity.
The model described midazolam concentrations in the
original dataset (Figure 2, panels A and B) and was able to pre-
dict midazolam clearance and plasma concentrations with-
out bias in critically ill children [13] and children after
cardiac bypass surgery [14] (Figure 2, panels C–F). In addition,
no trends were observed in CWRES vs. predicted plasma con-
centrations (plot not shown), conﬁrming that there was no
bias in the peak and trough concentration predictions. In ad-
dition, the MPE was <30% for both concentrations and clear-
ances (Table 2). The NPDE results indicated that model
predictions are accurate without trends over time or concen-
tration range (see Figure S1). The mean of the NPDE for both
populations was not signiﬁcantly different from 0 (0.034 and
0.062, respectively), while the variance of the variability in
the external data was statistically signiﬁcantly larger than
predicted by the model (2.24 and 1.95, respectively). This in-
dicates that the concentrations in the population were accu-
rately predicted, but that more variability is observed in the
new data than is predicted by the model. Figure 3 shows that
the individual clearance predictions (data points), which are
based on the patient’s level of inﬂammation and organ fail-
ure, are scattered around the population clearance predic-
tions for patients with varying body weight and a CRP
concentration of 32 mg l–1 and one failing organ (black line).
The model building dataset included term neonates, but
no preterm neonates [22]. Extrapolation of model predictions
to preterm neonates without inﬂammation or organ failure
resulted in underprediction of the high plasma concentra-
tions at early time points (Figure 2, panels G and H), with
an MPE >60% for both datasets (Table 2). The NPDE results
also indicated biased model predictions and an
underprediction of the variability (Figure S1, panels J–L).
Figure 3 shows that clearance was generally overpredicted
for this population.
When the model was used for extrapolation to healthy
adults without organ failure and an assumed CRP concentra-
tion of 10 mg l–1, midazolam clearances were within the pre-
dicted range (MPE <30%), albeit at the upper range, which
may be expected given their normal CRP concentrations
and lack of organ failure (Figure 3). However, in the
population-predicted vs. observed plot (Figure 2I), the
CWRES vs. time plot (Figure 2J) and the CWRES vs. popula-
tion-predicted concentration plot (not shown), a biphasic
trend was observed, causing a large overprediction of peak
and trough concentrations, and underprediction of other
plasma concentrations, which is suggestive of a
misspeciﬁcation of drug distribution. The NPDE (Figure S1,
panels M–O) also indicated this model misspeciﬁcation for
healthy adults. For critically ill adults with varying levels of
organ failure and an assumed CRP concentration of 32 mg l–1,
midazolam clearances were also predicted within the range
(MPE <30%), although in the lower range (Figure 3). Further-
more, the plasma concentrations were predicted with reason-
able accuracy (Figure 2, panels K and L). However, the NPDE
also showed some model misspeciﬁcation (the mean distribu-
tion error is signiﬁcantly different from 0; see Figure S1), which
may result from inappropriate information on drug
distribution.
Discussion
In the present analysis, the predictive performance and ex-
trapolation potential of a recently developed population PK
model for midazolam, quantifying CYP3A-mediated clear-
ance in critically ill children [6], were evaluated. According
to the applied model evaluation methods, midazolam clear-
ance and plasma concentrations are well predicted in exter-
nal data from critically ill children, infants and term
neonates, and children after cardiac bypass surgery who are
in the same age range and have similar levels of inﬂammation
and organ failure. Extrapolation to subjects outside the age
range and with different levels of disease severity resulted in
biased clearance for preterm neonates and biased concentra-
tion predictions in healthy adults. Extrapolation to subjects
outside the age range with similar levels of disease severity
(e.g. critically ill adults) resulted in adequate clearance predic-
tions (Figure 3).
To our knowledge, the evaluated PK model [6] in the pres-
ent study is the ﬁrst model to describe and quantify the rela-
tionship between inﬂammation and organ failure on
Table 2
Median prediction error (MPE) for predicted concentrations vs. observed concentrations, and individual predicted clearance vs. population-pre-
dicted clearance
Study
MPE (%)a
Plasma concentrations Clearance
Model building Vet et al. [6] 13.7 5.27
New data for external validation De Wildt et al. [13] 14.1 25.4
Valkenburg et al. [14] 3.1 22.0
New data for extrapolation De Wildt et al. [15] 63.5 1746
Jacqz-Aigrain et al. [16] 68.3 186
van Gerven et al. [17] 35.6 1.48
Swart et al. [18] 40.6 1.67
aTheMPE is the median of the prediction error, which reﬂects for plasma concentrations the difference in observed and predicted concentrations (see
Methods, Eq. (3)). For clearance, the difference in individual predicted and population-predicted clearance is calculated
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midazolam clearance in children. As in the model, besides
maturation, both inﬂammation and organ failure proved to
be of relevance, and these factors could be relevant for the
dosing of CYP3A substrates. However, model evaluation is es-
sential before a model can be used for clinical decision mak-
ing, such as developing dosing recommendations [7–10].
Ideally, a prospective study, with more subjects for external
evaluation, should be undertaken, to ensure that patient
characteristics and covariate information are recorded in
a standard way. However, with literature data available
[13–18], it would be unethical and unnecessary to put ad-
ditional burden on these vulnerable paediatric critically ill
patients by performing another PK study [23].
The external validation of this model in cohorts of criti-
cally ill paediatric patients and infants after cardiac bypass
surgery also conﬁrmed the accuracy of the relationships ob-
tained in patients who were not included in model building.
The PK model predicted a 30% decrease in midazolam clear-
ance when CRP concentrations that reﬂect the presence of in-
ﬂammation increase threefold from 32 mg l–1 to 100 mg l–1,
irrespective of the cause of elevated CRP concentrations,
which could be respiratory disorders, cardiac disorders, sepsis
or (non-)cardiac surgery [6]. Clearance decreased by 26%
when disease severity, expressed as the number of failing or-
gans, increased from one to two (Figure 1). Cardiovascular, re-
nal, respiratory, haematological and hepatic failure each
Figure 2
Goodness-of-ﬁt plots, stratiﬁed per study. First column (A, C, E, G, I, K) shows the population predicted concentrations versus the observed
concentrations and the second column (B, D, F, H, J, L) shows the conditionally weighted residuals (CWRES) over time for the different indicated
patient populations. For panels G-H, closed squares (◼) represent predictions from preterm neonates from the study of De Wildt et al. [15], while
open squares (◻) are data from preterm neonates from the study of Jacqz-Aigrain et al. [16]
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contributed to the number of failing organs, in which e.g. car-
diac failure andmechanical ventilationmay cause changes in
cardiac output, thereby having an impact on midazolam
clearance. As during an intensive care unit (ICU) stay, the
number of failing organs and CRP concentrations may
change over time, thereby inﬂuencing midazolam clearance,
so drug dosing in clinical practice may require adjustments
over time, assuming the same effective concentration. In
any case, it seems advisable to monitor the effects of midazo-
lam during the ICU stay in patients with major inﬂammation
and/or organ failure. This may be especially relevant in pre-
term neonates, as there are known risks for adverse neurolog-
ical effects due to the immaturity of γ-aminobutyric acid
(GABA) receptors. By evaluating the effects both in children
and adults, the fact that target plasma concentrations may
be inﬂuenced by inﬂammation or organ failure is also taken
into account. Whether these results for midazolam also apply
to other CYP3A substrates needs further study, and therapeu-
tic drug monitoring may be required in the case of a small
therapeutic window for the CYP3A substrate involved.
Many PK studies on the CYP3A substrate midazolam
[24–26] have been performed in children over the past two de-
cades [27–37], ranging from critically ill children to relatively
healthy children undergoing elective surgery, and we com-
pared our clearance predictions to the reported clearance
values in the literature, from studies up to 25 years ago
(Figure 4). The clearance values predicted by our model were
within the reported ranges, albeit in the lower range and with
high variability. High interindividual variability in clearance
in children is partly due to maturation of CYP3A-mediated
metabolism [38], but CYP3A activity is also known to be
downregulated by inﬂammatory cytokines in vitro [3]. The rea-
sons for our model predictions being generally lower than the
paediatric values reported in the literature (Figure 4) might
Figure 2
(Continued)
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have been due to differences in disease states, as the ‘healthi-
est’ children in our study still had one failing organ and were
still admitted to the ICU, while reported values in the litera-
ture mainly originated from non-ICU children. This suggests
that within a certain age and weight range, the disease state
is relevant for drug dosing. For example, for paediatric oncol-
ogy patients with acute-phase inﬂammatory disease, a de-
creased midazolam clearance has been reported [39], while
for relatively healthy children undergoing elective craniofa-
cial surgery, a much higher midazolam clearance has been re-
ported [28].
A limitation of comparing results with literature values is
that some studies report only summarized clearance data,
which are less informative than individual data. Moreover,
the clearance values described in the literature are mostly
reported per kg body weight [29–37], without reporting
the individual body weight values or body weight ranges
[32, 33, 35, 37]. Furthermore, detailed information on inﬂam-
mation and/or organ failure is missing in these studies.
The external validation of our model conﬁrmed accurate
predictions of the pharmacokinetics of midazolam in criti-
cally ill children. However, the results also showed that the
model should not be used for extrapolations to younger pop-
ulations or populations with different levels of disease sever-
ity. Clearance was largely overpredicted in preterm neonates
with a body weight below 3.5 kg and a gestational age of less
than 37 weeks, which is likely to be due to biased maturation
predictions of CYP3A activity and/or abundance in these
young patients, or possibly the lower level of inﬂammation
and organ failure in this patient group. Owing to rapid matu-
ration after birth, which is not accounted for in our model,
CYP3A capacity is likely to be overpredicted in our model.
Based on the current data, however, it is not possible to dis-
criminate between maturation and disease severity in this
population. The disease state in the neonatal ICU population
is known to be highly diverse, and, unfortunately, informa-
tion on CRP levels was not available for most of the preterm
Figure 3
Population (line) and individual (symbols) predicted clearance vs. the patient’s body weight. The population prediction assumes an individual
with a C-reactive protein (CRP) concentration of 32 mg l–1 and one failing organ. The grey shaded area indicates the range of population-pre-
dicted clearance values from the healthiest patients [without inﬂammation (CRP 10 mg l–1) and without organ failure] (upper boundary) to the
patient with the most severe disease state (CRP 300 mg l–1 and >3 failing organs) (lower boundary)
Figure 4
Population predicted clearance (oblique line) vs. the patient’s body
weight compared with literature-reported clearance values (open
squares with error bars) [28–37]. The population prediction assumes
an individual with a C-reactive protein (CRP) concentration of 32 mg
l–1 and one failing organ. The grey shaded area indicates the range of
population-predicted clearance values from the healthiest patients
[without inﬂammation (CRP 10 mg l–1) and without organ failure]
(upper boundary) to the patient with the most severe disease state
(CRP 300 mg l–1 and >3 failing organs) (lower boundary). The
squares represent the reported clearance for a mean body weight.
The horizontal error bars represent the included body weight range
or the body weight range derived from the patient’s age [42–44].
Vertical error bars represent the total range of reported clearances or,
in the case of one study, the 95% conﬁdence interval. Literature data
were obtained after a search of PubMed, with keywords including
midazolam, clearance, paediatric, children and pharmacokinetics, and
additional studies were identiﬁed from reviews and summarizing
studies [27, 45–50]. Studies published up to25 years agowere included
if paediatric subjects in the study received intravenously administered
midazolam. Studies with only preterm neonates and patients receiving
extracorporeal membrane oxygenation treatment were excluded
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infants. Assuming CRP values lower than 10 mg l–1 would re-
sult in higher predictions of clearance, rather than lower
clearance, and with more failing organs (e.g. 1–4), the pre-
dicted clearance would be up to 47.3% lower, while the ob-
served clearances in this population are even lower.
Therefore, until the additional maturation processes in pre-
term neonates are accounted for in the model, it should not
be used for extrapolation to this very young and critically ill
population.
The extrapolation to adults included healthy and critically
ill subjects alike. In the healthy adult population, clearance
was well predicted, assuming normal CRP levels and the lack
of organ failure that would be expected (Figure 3); however,
the drug distribution was misspeciﬁed, resulting in a clear
trend in the CWRES vs. time plot (Figure 2J). This biphasic
trend suggests that an additional peripheral compartment is
required to describe the distribution after a single (semi-) bolus
dose applied in adults. In the healthy volunteer study, more
samples were taken directly after dosing, possibly allowing
for the identiﬁcation of relatively fast-equilibrating peripheral
compartments (Figure 2J). In critically ill adults who were less
densely sampled, this trend in CWRES was indeed not ob-
served (Figure 2L). Other possible explanations for these obser-
vations could be altered plasma protein binding in critically ill
patients, whichmay alter drug distribution or capillary leaking
in such patients [40]; this may result in ultra-fast equilibration
of central and peripheral compartments. This ultra-fast equili-
bration in these patients prevents the identiﬁcation of periph-
eral compartments that can be identiﬁed in healthy patients
without capillary leaking.
In critically ill adults, midazolam clearance values were
predicted in the lower range of the expected clearance values
(Figure 3). This indicates that, despite the different age and
weight range in the external validation data, the model was
able to predict clearance in the critically ill adults with similar
levels of inﬂammation and organ failure.
Some limitations of the present extrapolation study
should be acknowledged. As CRP concentrations were not
available for all studies, the assumption was made that in
healthy adults and preterm neonates, CRP was 10 mg l–1
and that in critically ill adults this inﬂammation marker had
the median value of the internal dataset, of 32 mg l–1. To as-
sess the impact of different CRP concentrations on clearance
predictions, model-based simulations were performed, with
CRP values of 10 mg l–1 and 300 mg l–1 (see Figure 3, outer
boundaries of the grey area). For preterm neonates in the neo-
natal ICU, assuming CRP values of 1 mg l–1 or 300 mg l–1
would both result in the overprediction of midazolam clear-
ance (probably due to immature CYP3A in this population),
while for critically ill adults, assuming a value of 10 mg l–1
or 300 mg l–1, yields an prediction of their clearance values
within the predicted range (Figure 3, grey area). The model
should therefore not be extrapolated to preterm infants. In
our study, we could not account for genetic variation in
CYP3A4/5 activity, as in the original dataset the variability
in genotype was too low to identify a statistically signiﬁcant
impact of CYP3A4/5 genotype on midazolam clearance, and
in the datasets of the current study, information on genotype
was not available. However, in the literature it has been sug-
gested that patients with expression of functional CYP3A5
metabolize midazolam faster and may compensate for the
suppression of CYP3A4 activity due to inﬂammation or organ
failure [41]. These genotypes may also be of relevance in the
different populations studied here but, given the data ob-
tained in the present study, this could neither be conﬁrmed
nor rejected.
Finally, despite the adequate extrapolation potential of our
model to the patient populations included in the current
study, it should be noted that extrapolation to (special) popula-
tions not included in the current analysis (e.g. obese patients,
pregnant women) is not warranted without ﬁrst formally eval-
uating the extrapolation potential to these populations.
Conclusion
The recently published paediatric PK model for midazolam,
quantifying the inﬂuence of maturation, inﬂammation and
organ failure, can be used for predictions of CYP3A-mediated
midazolam clearance in term neonates, children and adults
with varying levels of critical illness, including infants after
cardiac bypass surgery and healthy adults. Using the model
for extrapolation resulted in biased predictions of clearance
in preterm neonates. The predictive performance of our
model and its value for the development of paediatric dosing
regimens for midazolam and potentially other CYP3A sub-
strates was therefore conﬁrmed for term neonates, infants,
children and adults with varying levels of critical illness.
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Figure S1 Normalized prediction distribution error (NPDE)
results, stratiﬁed per subpopulation. The histograms in the
ﬁrst column show the overall distribution of the NPDE, and
the second and third columns show the NPDE vs. time and
the population-predicted plasma concentrations, respectively.
Mean and variance are tested for signiﬁcant difference from
0 and 1, respectively
*P < 0.05
**P < 0.001
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